Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Bryan A. Mehlhaff

Urology
Oregon Urology Institute Pc
2400 Hartman Ln, 
Springfield, OR 
Accepting New Patients
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
Oregon Urology Institute Pc
2400 Hartman Ln, 
Springfield, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Bryan Mehlhaff is an Urologist in Springfield, Oregon. Dr. Mehlhaff is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Enlarged Prostate (BPH), Ureteroscopy, and Reconstructive Urology Surgery. Dr. Mehlhaff is currently accepting new patients.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Urology
Licenses
Urology in OR
Hospital Affiliations
Mckenzie-Willamette Medical Center
Sacred Heart Medical Center - Riverbend
Mercy Medical Center
Peacehealth Cottage Grove Community Medical Center
Peace Harbor Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
ATRIO Health
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser
  • EPO
  • HMO
  • POS
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
PacificSource
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
Samaritan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

OREGON UROLOGY INSTITUTE PC
2400 Hartman Ln, Springfield, OR 97477
Call: 541-334-3350

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


9 Clinical Trials

A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Biological
Study Drugs: Aglatimagene besadenovec, Valacyclovir
Study Phase: Phase 3
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Biological, Drug
Study Drugs: Aglatimagene Besadenovec, Valacyclovir
Study Phase: Phase 2
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Tazemetostat, Abiraterone/prednisone, Enzalutamide
Study Phase: Phase 1/Phase 2
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
Enrollment Status: Completed
Publish Date: October 10, 2024
Intervention Type: Drug
Study Drugs: LAE001, Prednisone, Afuresertib
Study Phase: Phase 1/Phase 2
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Registry for Hereditary Cancer Risk Assessment and Genetic Testing Among Men With Prostate Cancer in the Community Urology Practice Setting
A Registry for Hereditary Cancer Risk Assessment and Genetic Testing Among Men With Prostate Cancer in the Community Urology Practice Setting
Enrollment Status: Completed
Publish Date: November 05, 2020
A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: August 28, 2019
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Enrollment Status: Terminated
Publish Date: August 19, 2019
Intervention Type: Biological
View 8 Less Clinical Trials

9 Total Publications

Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.
Journal: Advances in therapy
Published: June 04, 2023
View All 9 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kadi-ann A. Bryan
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kadi-ann A. Bryan
Urology

Good Samaritan Hospital Corvallis

3600 Nw Samaritan Dr, 
Corvallis, OR 
 (38.3 miles away)
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kadi-ann Bryan is an Urologist in Corvallis, Oregon. Dr. Bryan has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Congenital Mesoblastic Nephroma, Clear Cell Sarcoma, Wilms Tumor, Reconstructive Urology Surgery, and Nephrectomy. Dr. Bryan is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Jeffrey B. Woolsey
Urology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Jeffrey B. Woolsey
Urology

Oregon Urology Institute PC

2400 Hartman Ln, 
Springfield, OR 
 (0.1 miles away)
541-334-3350
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Woolsey is an Urologist in Springfield, Oregon. Dr. Woolsey is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, UPJ Obstruction, Ureteroscopy, and Nephrectomy. Dr. Woolsey is currently accepting new patients.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. David S. Dimarco
Urology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. David S. Dimarco
Urology

Oregon Urology Institute PC

2400 Hartman Ln, 
Springfield, OR 
 (0.1 miles away)
541-334-3350
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

David Dimarco is an Urologist in Springfield, Oregon. Dr. Dimarco is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Obstructive Uropathy, Wilms Tumor, Familial Wilms Tumor 2, Reconstructive Urology Surgery, and Nephrectomy. Dr. Dimarco is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mehlhaff's expertise for a condition
ConditionClose
    • Distinguished
    • Familial Prostate Cancer
      Dr. Mehlhaff is
      Distinguished
      . Learn about Familial Prostate Cancer.
      See more Familial Prostate Cancer experts
    • Prostate Cancer
      Dr. Mehlhaff is
      Distinguished
      . Learn about Prostate Cancer.
      See more Prostate Cancer experts
    • Advanced
    • Bladder Cancer
      Dr. Mehlhaff is
      Advanced
      . Learn about Bladder Cancer.
      See more Bladder Cancer experts
    • Enlarged Prostate (BPH)
      Dr. Mehlhaff is
      Advanced
      . Learn about Enlarged Prostate (BPH).
      See more Enlarged Prostate (BPH) experts
    • Muscle Invasive Bladder Cancer
      Dr. Mehlhaff is
      Advanced
      . Learn about Muscle Invasive Bladder Cancer.
      See more Muscle Invasive Bladder Cancer experts
    • Non-Muscle Invasive Bladder Cancer
      Dr. Mehlhaff is
      Advanced
      . Learn about Non-Muscle Invasive Bladder Cancer.
      See more Non-Muscle Invasive Bladder Cancer experts
    • Peyronie Disease
      Dr. Mehlhaff is
      Advanced
      . Learn about Peyronie Disease.
      See more Peyronie Disease experts
    • Urothelial Cancer
      Dr. Mehlhaff is
      Advanced
      . Learn about Urothelial Cancer.
      See more Urothelial Cancer experts
    • Experienced
    • Bilateral Hydronephrosis
      Dr. Mehlhaff is
      Experienced
      . Learn about Bilateral Hydronephrosis.
      See more Bilateral Hydronephrosis experts
    • Bladder Outlet Obstruction
      Dr. Mehlhaff is
      Experienced
      . Learn about Bladder Outlet Obstruction.
      See more Bladder Outlet Obstruction experts
    • Bladder Stones
      Dr. Mehlhaff is
      Experienced
      . Learn about Bladder Stones.
      See more Bladder Stones experts
    • Boils
      Dr. Mehlhaff is
      Experienced
      . Learn about Boils.
      See more Boils experts
    • Carbuncle
      Dr. Mehlhaff is
      Experienced
      . Learn about Carbuncle.
      See more Carbuncle experts
    • Chromophobe Renal Cell Carcinoma
      Dr. Mehlhaff is
      Experienced
      . Learn about Chromophobe Renal Cell Carcinoma.
      See more Chromophobe Renal Cell Carcinoma experts
    View All 34 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved